Toggle Nav
mobile icon
My Cart
Close
  • Menu
  • Setting

Bcr-Abl

Bcl-Abl is a constitutively activated chimeric tyrosine kinase which is the genetic abnormality expressed in patient with CML (chronic myeloid leukemia).

Items 1-10 of 19

Page
per page
  1. AG957
    C5826 AG957
    Summary: a tyrphostin that targets transforming Bcr-Abl fusion proteins
  2. GNF-7
    B6033 GNF-7
    Summary: Type II Bcr-Abl inhibitor
      insoluble in EtOH; insoluble in H2O; ≥5.48 mg/mL
  3. PD 166326
    C3677 PD 166326
    Summary: receptor tyrosine kinases inhibitor
      ≤25 mg/mL
  4. GNF 2
    A8603 GNF 2
    Summary: Bcr-Abl inhibitor
      insoluble in H2O; ≥18.7 mg/mL
  5. GNF 5
    A8604 GNF 5
    Target: Bcr-Abl
    Summary: Bcr-Abl inhibitor
  6. 1-Naphthyl PP1
    A8605 1-Naphthyl PP1
    Summary: Src family kinases inhibitor
      ≥25.32 mg/mL
  7. PD 180970
    A8606 PD 180970
    Summary: P210bcr/abl tyrosine kinase inhibitor
      <21.46 mg/mL
  8. PPY A
    A8607 PPY A
    Target: Abl kinases
    Summary: Abl kinases inhibitor
      <37.24 mg/mL
  9. PD173955
    A8812 PD173955
    Target: Bcr-Abl|Src
    Summary: Dual Src/Abl kinase inhibitor, ATP-competitive,
      ≥22.15 mg/mL
  10. GZD824
    B1402 GZD824
    Target: Bcr-Abl
    Summary: Bcr-Abl inhibitor,novel orally bioavailable
      ≥36.25 mg/mL

Items 1-10 of 19

Page
per page